

PRESS RELEASE

23rd June 2021

New images released of the world's first non-invasive wearable blood glucose sensor

New images have been released of the world's first wearable, non-invasive, real-time continuous blood glucose sensor which is tipped to have a "life-changing" impact on the global diabetes community.

With more than 463 million people worldwide believed to have diabetes, the Afon Technology blood glucose sensor is designed to be compatible with your chosen smart watch, phone or tablet.

The sensor sits on the inside of your wrist and uses Bluetooth technology to send real-time information to a companion app which will display your blood glucose trends and alert you to high/low glucose levels as well as personal health trends.

The new images have been released to demonstrate the innovative device's agnostic capability to be used with any smart watch.

Afon Technology's CEO Sabih Chaudhry said: "Our taskforce of experts are world-class and together we are delighted to share plans for this life-changing device for people with diabetes. Without using needles the pain-free Afon device will simply sit on the inside of your wrist and communicate vital information via Bluetooth to your chosen smart device.

"Diabetes can be incredibly limiting to someone's life, but we believe we've created a device which will provide the wonderful feeling of freedom all wrapped up in a watch on the wrist."

Tipped to completely radicalise the lives of those who have diabetes, the Afon device will go one step further than the revolutionary FreeStyle Libre. Unlike the Libre, it will measure blood glucose levels without the need to penetrate the skin at all, making it easier to manage the condition and therefore reducing the risk of diabetes-related complications such as heart attack, stroke, blindness, kidney failure and limb amputations.

Preliminary clinical research gives developers hope that such a device could become a reality in the near future.

Professor de Vries, Medical Director at Profil, the diabetes research organisation in Germany, who specialises in internal medicine and endocrinology and is a principal investigator at the University of Amsterdam's Faculty of Medicine (AMC-UVA), said: "We evaluated the Afon device under both hyper-and hypoglycaemic conditions during the clinical trials and we were surprised and excited by the possibilities of this technology."

With no replaceable parts it will be cheaper than other current diabetes technologies available on the market which rely on replacement patches and needles.

Companies such as Apple, Samsung and Google are rumoured to have been trying to develop non-invasive blood glucose monitoring, but so far none have been successful. Afon Technology hopes to win the race to this important milestone.

It is hoped the device, which is set to undergo another round of clinical trials, will be available to purchase from end-2022.

According to research £5.5bn of NHS hospitals' budget is spent on diabetes, and poor diabetes control was responsible for £3bn in potentially avoidable hospital treatment in England in the year 2017-2018.

The company, founded in 2015 and based in Wales, has already picked up a Healthcare and Pharmaceutical Award.



Notes to editors

- For further details, to arrange an interview or more photographs, email oliver.jelley@ojpr.co.uk or fiona.bailey@ojpr.co.uk
- Alternatively call 07803 003811 or 01604 882342